Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions

Cancer Prevention Research

Volumn 6, Issue 2, 2013, Pages 71-73

  Brenner, Dean E ^a   Hawk, Ernest ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; XANTHINE OXIDASE;

CALCIUM INTAKE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CELL CULTURE; COLON ADENOMA; COLON CANCER; HUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STEM CELL EXPANSION;

ADENOMA; ALLOPURINOL; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PREOPERATIVE CARE;

EID: 84874486867     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0499     Document Type: Review

References (13)

1. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, HongWK, Fabian CJ, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
2. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006;12:3661-97.
3. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010;70:7392-9.
4. Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, BurakWEJr, et al. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 2004;10:5403-17.
5. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri- Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012; 30:2593-600.
6. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001;10:861-8.
7. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL Jr. Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst 2001; 93:57-9.
8. Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, et al. Effect of low-fat diets on plasma levels of NF-kappaB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res 2011;4:1590-8.
9. Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT IV, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008;17:3577-87.
10. Lee J, Lippman S, Benner S, Lee J, Ro J, Lukeman J, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994;12:937-45.
11. Puntoni M, Branchi D, Argusti A, Zanardi S, Crosta C, Meroni E, et al. A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma. Cancer Prev Res 2013;6:74-81.
12. Lieberman DA. Clinical practice. Screening for colorectal cancer. N Engl J Med 2009;361:1179-87.
13. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 2010;122:777-85.